不同病程的帕金森病患者血清Aβ1-42、YKL-40、BDNF水平变化及其临床意义

目的 探究不同病程的帕金森病患者血清Aβ1-42、YKL-40、BDNF水平变化及其临床意义。方法 收集2016年6月-2018年5月来本院治疗的PD患者150例为观察组,选取150例健康志愿者为对照组,测定观察组与对照组血清中的Aβ1-42、YKL-40、BDNF水平。结果 观察组和对照组的Aβ1-42、YKL-40、BDNF水平存在显著性差异(P<0.05),与对照组比较,观察组的YKL-40水平明显升高(P<0.05),Aβ1-42水平显著降低(P<0.05),虽然BDNF水平有降低趋势,但无明显差异(P>0.05)。早期患者的血清YKL-40水平明显低于中晚期患者(P<0.05)。 Spearman秩和相关分析显示,血清YKL-40水平与PD患者病程呈正相关(r_s=0.01,P<0.05)。结论 PD患者血清中的YKL-40水平明显升高,Aβ1-42水平显著降低,且早期PD患者的血清YKL-40水平明显低于中晚期PD患者,血清YKL-40水平可能有助于判断PD患者的病程。     

帕金森病患者血清人软骨糖蛋白39水平的改变及其与病情和认知功能的相关性

目的探讨帕金森病(PD)患者血清人软骨糖蛋白39(YKL-40)水平的改变及其与病情和认知功能的相关性。方法用ELISA法给63例PD患者和60名正常对照者进行血清YKL-40水平检测,以及蒙特利尔认知评估(Mo CA)量表评分。并给PD患者进行统一PD评定量表(UPDRS)Ⅰ、Ⅱ、Ⅲ评分,评定病情。对PD患者的血清YKL-40水平与UPDRSⅠ、Ⅱ、Ⅲ评分、病程及Mo CA量表进行相关性分析。结果 PD组的血清YKL-40水平[(3.717±0.1015)ng/ml]明显高于正常对照组[(2.919±0.1827)ng/ml](P0.001)。PD患者的血清YKL-40水平与UPDRSⅠ无相关性(r=0.21,P0.05),与UPDRSⅡ、Ⅲ评分呈正相关(r=0.9251,r=0.7767;均P0.0001),与PD患者的病程亦呈正相关(r=0.4323,P0.01),与Mo CA量表评分呈负相关(r=-0.6985,P0.0001)。结论 PD患者的血清YKL-40水平显著增高,并与病情和认知功能密切相关。YKL-40可成为PD诊断和病情判断的生物学指标。     

小牛血清去蛋白联合鼠神经生长因子治疗自发性脑出血的疗效分析及对血清cFN、YKL-40水平的影响

目的 探讨小牛血清去蛋白联合鼠神经生长因子治疗自发性脑出血的疗效及对血清cFN、YKL-40水平的影响。方法 选择2016年2月-2018年12月在本院接受治疗的80例脑出血患者作为研究对象,按照简单随机法将患者分成观察组及对照组,每组各40例; 对照组患者采取小牛血清去蛋白治疗,观察组患者采取小牛血清去蛋白联合鼠神经生长因子治疗; 观察2组患者的的疗效、生活质量及血清cFN、YKL-40水平。结果 与对照组比较,观察组患者的有效率更高(χ2=9.493,P<0.05)。与干预前比较,2组患者干预后的cFN水平、YKL-40水平明显更低(t=7.492、8.284,8.492、10.494,P<0.05); 与对照组比较,观察组患者干预后cFN水平、YKL-40水平明显更低(t=8.320、9.492,P<0.05); 与对照组比较,观察组患者的生活质量评分明显更优(t=8.204、9.023、10.323、8.492、8.692、9.432、10.953、8.242,P<0.05)。结论 小牛血清去蛋白联合鼠神经生长因子可明显提高自发性脑出血患者的疗效,降低患者的血清cFN、YKL-40的表达水平。     

盐酸多奈哌齐对MCI患者MoCA评分和认知功能的影响

目的 探讨盐酸多奈哌齐对轻度认知障碍(MCI)患者蒙特利尔认知评估量表(MoCA)评分和认知功能的影响. 方法 哈尔滨医科大学附属第一医院神经内科自2010年9月至2011年3月共收治MCI患者50例,其中给予盐酸多奈哌齐治疗30例(盐酸多奈哌齐组),银杏叶片治疗20例(对照组),分析并比较2组患者治疗前、治疗12周、24周后MoCA评分的变化. 结果 盐酸多奈哌齐组患者治疗12、24周时MoCA评分高于治疗前,差异有统计学意义(P＜0.05).治疗12周、24周时盐酸多奈哌齐组MoCA评分均高于对照组,差异有统计学意义(P＜0.05);治疗12周时盐酸多奈哌齐组患者在数字广度、词语流畅性和延迟记忆方面的分项得分高于治疗前,差异有统计学意义(P＜0.05). 结论 MoCA量表能够对MCI患者进行早期诊断,盐酸多奈哌齐对MCI患者进行早期治疗能延缓其进入AD的病程.     

YKL-40与视神经脊髓炎谱系障碍患者神经功能的相关性

目的 分析AQP-4阳性视神经脊髓炎谱系障碍(NMOSD)患者血清及脑脊液YKL-40水平及其与疾病严重程度的相关性。方法 搜集2022-01—12郑州大学第一附属医院30例AQP-4阳性的视神经脊髓炎谱系障碍患者,并纳入24例年龄、性别相匹配的非炎症性神经系统疾病(ONND)患者及24名健康对照者。采用酶联免疫吸附试验测定YKL-40水平,并对所有患者进行扩展残疾状态量表(EDSS)评定。结果 AQP-4阳性的视神经脊髓炎谱系障碍患者脑脊液YKL-40水平(314.3±42.9)μg/L,明显高于ONND患者(127.2±19.9)μg/L,P<0.001。MRI增强病变患者脑脊液YKL-40水平(324.7±43.7)μg/L,明显高于未出现MRI增强病变的患者(290±31.3)μg/L,P=0.041。视神经脊髓炎谱系障碍患者脑脊液YKL-40水平与EDSS得分呈正相关(r=0.372,P=0.043)。结论 YKL-40可作为AQP-4阳性的视神经脊髓炎患者严重程度的生物标志物和治疗NMOSD的潜在靶点。     

短暂性脑缺血发作患者认知功能与蒙特利尔认知评估量表评分、事件相关电位及血清神经元特异性烯醇化酶水平的关系

目的 探讨短暂性脑缺血发作(TIA)患者认知功能与蒙特利尔认知评估量表(MoCA)评分、事件相关电位(P300)及血清神经元特异性烯醇化酶(NSE)水平的关系.方法 61例TIA患者,在其最近发作3 d内进行MoCA、P300及血清NSE检测,并与40名健康对照者(正常对照组)进行比较.结果 TIA组的MoCA评分[(16.59±5.74)分]、P300潜伏期[(355.50±38.52)ms]及P300波幅[(3.11±1.65)μV]、血清NSE水平[(18.95±8.78)ng/ml]与正常对照组[(27.58±1.36)分、(310.66±30.12)ms、(5.22±2.72)μV、(11.34±4.67)ng/ml]比较差异有统计学意义(均P＜0.01).TIA≤5次患者MoCA评分、P300潜伏期及血清NSE水平与TIA＞5次患者比较差异有统计学意义(均P＜0.01).相关性分析显示,TIA患者MoCA评分与P300潜伏期、血清NSE水平负相关(r=-0.444,r=-0.447;均P＜0.01),P300潜伏期与血清NSE水平正相关(r=0.425,P＜0.01).TIA组中,MoCA异常率(86.9%,53例)显著高于P300潜伏期的异常率(37.7%,23例)(P＜0.01).结论 MoCA、P300检测能反映TIA患者的认知功能损害,并与血清NSE水平相关.MoCA评分对TIA认知功能损害的识别优于P300.     

帕金森病患者血清EGF和BDNF水平变化与认知障碍的关系

目的探讨帕金森病(PD)患者血清表皮生长因子(EGF)和脑源性神经营养因子(BDNF)的变化及其与认知功能的关系。方法入选PD患者76例和年龄、性别相匹配的40例健康对照组,记录PD患者的性别、年龄、病程、受教育年限、HoehnYahr(H-Y)分级,采用蒙特利尔认知评估量表(Mo CA)对所有研究对象认知功能进行评估,采用酶联免疫吸附法(ELISA)检测血清EGF和BDNF水平,并对结果进行分析。结果 PD组血清EGF、BDNF水平明显低于健康对照组[(745±148)ng·L~(-1)比(952±157)ng·L~(-1),P0.05;(5.1±3.1)μg·L~(-1)比(6.8±3.9)μg·L~(-1),P0.05];早期PD组与中晚期PD组血清EGF和BDNF水平无差异(P0.05);但合并轻度认知功能障碍(MCI)的PD组血清EGF水平低于无MCI的PD组[(713±146)ng·L~(-1)比(865±189)ng·L~(-1),P0.01];PD患者Mo CA评分与受教育年限(β=0.611,P0.01)、血清EGF水平(β=0.513,P0.01)呈正相关,与病程(β=-0.373,P0.05)、H-Y分级(β=-0.264,P0.05)呈负相关。结论 EGF和BDNF水平的改变可能参与了PD患者的发病机制;血清EGF水平的下降可能与PD患者的MCI具有相关性,其可能为PD患者合并认知功能障碍的潜在早期预测指标。     

血清YKL-40水平与胶质瘤病理分级及预后的相关性研究

目的探讨血清YKL-40水平与胶质瘤病理分级及预后的相关性。方法选取诊断为脑胶质细胞瘤并行手术治疗的成年病例68例为胶质瘤组,20例健康体检病人作为对照组,根据术后病理学分级,低度恶性Ⅰ级2例、Ⅱ级17例,高度恶性Ⅲ级15例、Ⅳ级34例。观察生存时间及复发时间,生存时间〈12个月15例,12～24个月15例,〉24个月38例。复发前死亡10例,复发时间〈12个月14例,12～24个月15例,〉24个月未复发29例。术前均抽取静脉血采用酶联免疫吸附试验（ELISA）测定血清YKL-40水平。结果低级别（I级、Ⅱ级）胶质瘤病人血清YKL-40水平与对照组无显著差异（P〉0.05）,Ⅳ级胶质瘤病人血清YKL-40水平显著高于其他组（P〈0.05）。生存时间〈12个月和12～24个月的病人血清YKL-40水平显著高于生存时间〉24个月的病人（P〈0.05）。复发病人血清YKL-40水平显著高于未复发者（P〈0.05）,12个月内复发的病人血清YKL-40水平显著高于12～24个月复发的病人（P〈0.05）。结论血清YKL-40水平与胶质瘤的病理学分级及预后密切相关,可作为恶性程度及预后的判断指标。     

多系统萎缩患者血清YKL-40和CD40水平变化及相关性因素研究

目的探讨多系统萎缩(MSA)患者血清几丁质酶3样蛋白1(YKL-40)、CD40水平的变化,以及其与发病年龄、病程、疾病严重程度的相关性。方法病例组为2013-03-01—2014-11-30期间大连医科大学附属第一医院神经内科的住院MSA患者30例,其中很可能MSA24例,可能MSA6例,均符合2008年修订Gilman诊断标准;对照组为同期年龄和性别相匹配的30例健康体检者。利用酶联免疫吸附试验(ELISA)检测血清YKL-40与CD40水平,并分析两者与MSA患者性别、年龄、发病年龄、病程和疾病严重程度〔以统一多系统萎缩评估量表(UMSARS)Ⅱ评分进行评估〕的相关性。结果 MSA患者血清YKL-40水平〔38.32(11.74)ng/mL〕较对照组〔47.2(13.88ng/mL〕降低(t=238.00,P=0.002);对照组不同性别间〔男(36.23±9.74)ng/mL,女(36.50±10.86)ng/mL,t=0.519,P=0.477)〕及病例组不同分型间〔MSA-C型:40.67(13.09)ng/mL,MSA-P型:38.24(9.90)ng/mL,U=104.00,P=0.739〕比较血清YKL-40水平差异均无统计学意义。MSA患者血清中CD40水平〔120.39(39.47)pg/mL〕较对照组〔116.12(35.85)pg/mL〕差异无统计学意义(t=439.00,P=0.871)。对照组血清YKL-40水平与年龄无明显相关性(P0.05),病例组血清YKL-40水平与患者发病年龄、病程和UMSARSⅡ评分均无相关性(均P0.05);ROC曲线分析显示血清YKL-40水平对MSA无明确诊断价值(AUC=0.264,P=0.002)。结论 MSA患者血清YKL-40水平较健康人显著降低。MSA患者YKL-40水平与发病年龄、病程和UMSARSⅡ评分无相关性。     

Elevated cerebrospinal fluid and serum YKL-40 levels are not associated with symptomatic vasospasm in patients with aneurysmal subarachnoid haemorrhage

YKL-40 is a newly discovered matrix protein that is thought to be released during the acute stages of inflammation. It has recently been speculated that YKL-40 may serve as a specific serological marker of neutrophil function at the site of tissue inflammation. Our aim was to determine whether the levels of YKL-40 in both the cerebrospinal fluid and sera of 22 patients with aneurysmal subarachnoid haemorrhage were associated with either vasospasm or outcome. The levels were also compared with those of 16 control patients with hydrocephalus. We found that patients with aneurysmal subarachnoid haemorrhage had significantly higher YKL-40 levels in both cerebrospinal fluid and serum than controls. However, elevated YKL-40 levels were not associated with symptomatic vasospasm or 6-month outcome. We show that elevated YKL-40 levels are not correlated with the severity of subarachnoid haemorrhage and cannot be used as a serological marker of inflammation in patients with an aneurysm rupture.     

自发性脑出血患者血清YKL-40动态变化与预后关系研究

目的观察自发性脑出血(ICH)患者血清YKL-40水平与脑出血量、神经功能损伤的关系,分析影响ICH患者预后的危险因素。方法选择自发性基底节区脑出血患者100例作为实验组,根据神经损伤程度进一步分为轻度损伤30例,中度损伤46例,重度损伤24例,以及根据脑出血量分为小量出血(10 ml)35例,中量出血46例(10~30 ml),大量出血19例(30 ml),另选择同期门诊健康体检者50例作为对照组,分别检测患者第1、3、7和14天血清YKL-40水平。3月后通过mRS评分评价患者预后情况,采用多因素Logistic回归方法分析影响患者预后的独立危险因素。结果实验组患者YKL-40水平明显高于对照组(P0.001)。小量出血、中量出血、大量出血患者的血清YKL-40水平均在7天内逐渐升高,且在第7天达到最大值,随后逐渐下降(P0.05)。重度神经损伤患者的血清YKL-40水平明显高于中度、轻度损伤患者(P0.05)。3月时预后良好组为54例,预后不良组为32例。多因素Logistic回归分析显示,年龄、入院时NIHSS评分、出血破入脑室、YKL-40是影响自发性脑出血患者预后的独立危险因素。结论自发性脑出血患者的血清YKL-40水平与患者的脑出血量及神经功能损伤程度存在相关性,可为自发性脑出血患者临床诊疗及预后判断提供依据。     

Circulating interleukin-15 and RANTES chemokine in Parkinson's disease

Interleukin-15 promotes T-cell proliferation, induction of cytolytic effector cells including natural killer (NK) and cytotoxic cells and stimulates B-cell to proliferate and secrete immunoglobulins. RANTES is a C-C beta chemokine with strong chemoattractant activity for T lymphocytes and monocytes. OBJECTIVES: The objective of our study was to find out whether IL-15 and RANTES are involved in the possible inflammatory reactions of PD. PATIENTS AND METHODS: We measured by immunoassay serum IL-15 and RANTES levels in 41 patients with PD in comparison with serum levels in 19 healthy subjects age and sex-matched. IL-15 and RANTES levels were correlated with sex, age, disease duration. H-Y stage and the UPDRS III score in all the studied groups and were also correlated with treatment status in PD patients. RESULTS: The PD group presented with significantly increased RANTES levels as compared to the control group (P = 0.0009). No difference was observed as regards IL-15 levels. A strong and significant correlation between RANTES levels and UPDRS III score was observed in PD patients (R(s) = 0.42, P = 0.007). Untreated patients had significantly higher RANTES levels as compared to the controls. CONCLUSIONS: Our findings may suggest a recruitment of activated monocytes, macrophages and T lymphocytes to sites of inflammation in the central nervous system of PD patients.     

血清YKL-40蛋白水平与颈动脉斑块内新生血管形成的关系

目的 探讨血清YKL-40蛋白水平与颈动脉斑块内新生血管形成的关系。方法 收集2015年1月～2016年12月本院超声科首次发现有颈动脉斑块者575例为研究组,以同期无动脉斑块者500例为对照组; 应用超微血管成像(SMI)技术判断斑块内新生血管分级,并检测研究对象的血清YKL-40蛋白、血脂、炎性因子TNF-α、hsCRP、IL-6等指标水平。结果 ①与对照组比较,研究组TC、TG、LDLC水平明显升高,HDLC明显降低(P均<0.05); ②研究组的IL-6、TNF-α、hsCRP、Lp-PLA2、YKL-40蛋白水平与对照组存在明显差异(P<0.05); ③按SMI分级将研究组患者分为4组,4组患者的YKL-40蛋白、IL-6、TNF-α、hsCRP、Lp-PLA2、血脂水平存在明显差异(P均<0.05); ④YKL-40蛋白与炎性因子及血脂指标水平存在相关性(P均<0.05)。结论 血清YKL-40蛋白水平与颈动脉斑块内新生血管形成的严重程度有关,检测YKL-40蛋白水平对判断斑块的稳定性有益。     

帕金森病患者周围神经病变与血清叶酸维生素B_(12)水平的相关性

目的分析帕金森病患者周围神经病变与血清叶酸、维生素B12水平的相关性。方法随机选取100例帕金森病患者为病例组,同时选取与病例组性别、年龄、身体条件、生活区域相似的100例健康人为对照组,比较2组周围神经病变的发病情况以及血清叶酸、维生素B12水平。结果病例组周围神经病变发病率42.0%,对照组为16.0%,病例组明显高于对照组(P0.05)。病例组尺神经、正中神经传导速度虽较对照组有所降低,但差异无统计学意义(P0.05);病例组周围神经受损者的腓肠神经、胫神经传导速度明显较对照组低(P0.05),但病例组无周围神经受损者的腓肠神经、胫神经传导速度较对照组虽有所降低,但只与对照组无周围神经受损者差异有统计学意义(P0.05)。对照组维生素B12以及叶酸的浓度较病例组高,且其浓度与病例组患者的周围神经受损程度有明显的正相关性;病例组无周围神经受损者的维生素B12以及叶酸浓度较对照组中周围神经受损者低(P0.05)。结论帕金森病患者周围神经病变与血清叶酸、维生素B12水平呈负相关,患者血清叶酸、维生素B12水平越低,发生周围神经病变的可能性越大,病情越重。     

Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration

There is evidence to support that oxidative stress is increased in Parkinson's disease (PD) and contributes to degeneration of dopaminergic neurons. Uric acid (UA), a natural antioxidant in blood and brain tissue, scavenging superoxide, peroxynitrite and hydroxyl radical, was found reduced in the serum of PD patients. In addition low plasma uric acid (UA) levels have been associated with an increased risk of PD.

Objectives

The aim of our study was to investigate serum UA levels in PD patients compared with age-matched healthy controls and their possible relationship with several clinical parameters of PD and pharmaceutical treatment.

Patients and methods

We measured serum UA levels in 43 PD patients and 47 healthy volunteers, age and sex-matched. UA levels were correlated with disease duration, severity and treatment.

Results

Low UA levels were observed in PD patients compared with controls (p = 0.009). Age, Body Mass Index (BMI) and UPDRS III score did not significantly affect serum UA concentrations, whereas gender was found to contribute significantly to UA level (p < 0.000). Strong and significant inverse correlations of UA with disease duration (R_s = −0.397, p = 0.009) and daily levodopa dosage (R_p = −0.498, p = 0.026) were observed. These associations were significant for men (R_s = −0.441, p = 0.04 and R_s = −0.717, p = 0.03 respectively), but not for women (R_s = −0.221, p = 0.337 and R_s = −0.17, p = 0.966 respectively).

Conclusion

Our results suggest that there may be increased consumption of UA as a scavenger in PD, possibly heightened by dopaminergic drug treatment. Given the antioxidant properties of UA, manipulation of its concentrations should be investigated for potential therapeutic strategies of the disease.     

Plasma levels of inorganic sulfates in patients with Parkinson's disease

Some investigators reported pharmacogenetic differences in the metabolism of sulfur-containing drugs and lower plasma sulfate levels in patients with Parkinson's disease (PD) compared with controls. However, other group did not confirm these findings. We studied the plasma levels of sulfate by indirect atomic absorption spectrophotometry in 55 PD patients and 57 age and sex-matched controls. The plasma sulfate levels did not differ significantly between PD patient and control groups (mean ± SEM 73 ± 8 and 75 ± 7 mg/1, respectively). They were not influenced by antiparkinsonian drugs and they did not correlate with age at onset, duration, Hoehn & Yahr staging or activities of daily living subscale of the Unified Parkinson's disease rating scale. There was a low but significant correlation of plasma sulfate levels with motor examination ( r = - 0.36, p < 0.05) and total score ( r =−0.33, p < 0.05) of this scale in the PD group. These data suggest that plasma sulfate levels are apparently unrelated with the risk for PD.     

Serum and urinary manganese levels in patients with Parkinson's disease

To elucidate the possible role of manganese in the risk of developing Parkinson's disease (PD), we compared serum levels of manganese, and 24-h manganese excretion by urine in 29 PD patients and in 27 matched controls. We also measured chromium and cobalt in the same samples. All these values did not differ significantly between the groups, they were not influenced by antiparkinsonian drugs, and they did not correlate with age, age at onset and duration of the PD, scores of the Unified PD Rating Scale or the Hoehn & Yahr staging in the PD group. These results might suggest that serum levels and urinary excretion of manganese are apparently unrelated to the risk of developing PD.